Is your data referring to the comparable stability of Lucentis and Avastin in the systemic circulation?... I was under the impression that in the vitreous, the FAb fragment has a longer half-life than it has in the vasculature... Gaudreault et al (IOVS 46:726, 2005) report that the half-life of Ranibizumab (Lucentis) in the monkey eye is about 3d. The inference (in your link to Dan Robert's summary) that Avastin would be around 100 times longer than Lucentis when injected into the eye seems unlikely to me.... Actually, I find all of the 6 arguements presented by Dan Roberts as concerns about Avastin's use as a replacement for Lucentis as being rather weak.
Market Data 
Markets 
AI
